| Ranok (Hangzhou, China) |
drug candidate RNK05047
entering clinical trials in the first half of 2022 for treatment of
solid tumors and lymphomas123
|
| Monte Rosa Therapeutics
(Boston, MA) |
initiated
IND-enabling activities
for its lead program targeting GSPT1 for oncology treatment and beyond;
IND application to be submitted to the FDA mid-2022; drug discovery
phase for other molecular glues targeting solid/liquid tumors, autoimmune
diseases, and blood diseases128
|
| Plexium/partnered with
Amgen
(San Diego, CA) |
lead
optimization phase
for a cereblon molecular glue targeting IKZF2 for the treatment of
immune disease and cancer; drug discovery phase for a disclosed novel
E3 ligase molecular glue and also undisclosed partnered molecular
glue programs129
|
| Frontier Medicines/partnered
with AbbVie (San Francisco, CA) |
drug discovery phase to
develop small molecule covalent drugs against intractable immunology
and oncology targets130
|
| f5 Therapeutics (San Diego,
CA) |
pipeline of molecular
candidates
for hepatocellular carcinoma, breast cancer, lung cancer, head and
neck cancer, colorectal cancer, gastric cancer, multiple sclerosis,
rheumatoid arthritis, nonalcoholic steatohepatitis, and liver fibrosis131
|
| Ambagon Therapeutics/partnered
with BMS and Merck (San Carlos, CA) |
drug discovery phase with
five early discovery oncology treatment compounds; focusing on targeting
gene signaling and expression and disrupting the cell cycle, along
with other cancer-causing dysregulations, Ambagon expects to have
at least one development candidate by the second quarter of 2023132
|
| Captor (Wrocław, Poland) |
drug candidates for hepatocellular
carcinoma and autoimmune liquid tumors133
|
| Amphista
Therapeutics (London,
U.K.) |
aims to move
beyond use
of ubiquitin E3 ligase cereblon; they will initially focus on cancer
treatments, with the possibility of branching out to treat neurological,
neurodegenerative, and immunological disease along with other areas
of high unmet medical need in the future134
|
| Dunad
Therapeutics (Cambridge,
U.K.) |
drug discovery
phase utilizing
central nervous system accessible therapeutics135
|
| Proxygen/partnered with
Boehringer Ingelheim (Vienna, Austria) |
drug discovery phase treating
lung and gastrointestinal cancers136
|
| Neomorph/partnered
with
Dana-Farber Cancer Institute (San Diego, CA) |
drug discovery phase to
advance their molecular glue development pipeline against undruggable
targets137
|
| Seed Therapeutics/partnered
with Lilly (New York, NY) |
drug discovery phase with
molecular glue pipeline candidates treating cancers, neurodegenerative
diseases, and infectious diseases; their lead compound targets the
KRAS oncogene138
|
| Pin Therapeutics (Seoul,
South Korea) |
drug
discovery phase139
|
| Venquis Therapeutics, (San
Diego, CA) |
drug discovery
phase for
cancer and degenerative diseases140
|
| IRB Barcelona/partnered
with Almirall (Barcelona, Spain) |
drug discovery phase for
skin disease treatment141
|
| Shanghai Dage Biomedical
Technology Co., Ltd. (Shanghai, China) |
pipeline of molecular glues
addressing targets for cancers, inflammatory disease, and metabolic
disease; lead optimization phase for oncology molecular glue candidates142
|
| Triana Biomedicines (Waltham,
MA) |
launched recently
in April
2022 to establish a rationally designed molecular glue pipeline to
treat inadequately addressed diseases143
|
| Evotec/partnered
with BMS
(Hamburg, Germany) |
drug discovery phase to
develop a pipeline of molecular glue degraders144
|
